A study found that CBD could be an effective treatment for cannabis dependency.
In a recent study published in the journal Lancet Psychiatry, researchers said they administered CBD or placebo to 82 participants who had unsuccessfully tried to quit using cannabis in the past.
In the first stage of the trial, 48 volunteers received either placebo or CBD at daily doses of 200mg, 400mg or 800mg. It was determined that 200mg of CBD had little to no effect on the patients, and the dose was dropped. During the second stage of the study, participants received either 400mg or 800mg doses of CBD. The treatment lasted for four weeks, and researchers performed follow-ups six months later.
The study determined that participants who received daily 400mg and 800mg doses of CBD were more successful at reducing cannabis use than the placebo group. These doses are significantly higher than those suggested for over-the-counter CBD products, but the study found no increase in side effects compared to the placebo group, indicating that the high doses are still tolerable to humans.
“The results from our trial open up a novel therapeutic strategy for managing problematic cannabis use in clinical settings,” said lead author Dr. Tom Freeman, director of the Addiction and Mental Health Group within the Department of Psychology at the University of Bath.
Another study has reportedly found a correlation between regular cannabis use among women and increased sexual gratification. A new study published in the journal Sexual Medicine found that women who frequently use cannabis often experience higher states of arousal, more pleasurable sex and more intense orgasms.
Researchers examined the results of an online survey of adults who visited cannabis dispensaries between October 2019 and March 2020. The survey assessed baseline demographics, health status and cannabis use habits. It also used the Female Sexual Function Index (FSFI)—a questionnaire that measured the participants’ sexual function.
According to the survey, women who use cannabis more than six times per week reported higher FSFI scores than those who smoked irregularly. An increase in the frequency of cannabis use by one additional use per week was reportedly associated with an increase in total FSFI as well. And for each incremental increase of cannabis use per week, the odds of reporting female sexual dysfunction declined by 21 percent.
The study found that the method of consumption and the product’s cannabinoid profile had no significant impact on FSFI.